



# The significant role of point-of-care coagulation studies: shorter cardiac surgery, better renal function and tranexamic acid cannot alone reduce early platelet transfusions

Kimberly L. Skidmore,<sup>1,2</sup> Grant Borne,<sup>3</sup> Anusha Kallurkar,<sup>1</sup> Denisa Pavlickova,<sup>1</sup> Dariusz Myrcik,<sup>4</sup> Giustino Varrasi,<sup>5</sup> Sahar Shekoochi,<sup>1</sup> Alan D. Kaye<sup>6</sup>

Correspondence: Sahar Shekoochi, Department of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, 1501 Kings Highway, Shreveport LA 71103, USA. E-mail: sahar.shekoochi@lsuhs.edu

Key words: cardiopulmonary bypass; transfusions; platelets; tranexamic acid; thromboelastogram; fibrinogen; patient blood management.

Conflict of interest: the authors declare that they have no competing interests, and all authors confirm accuracy.

Contributions: all the authors made a substantive intellectual contribution, performed part of the experiments. All the authors read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work.

Ethics approval and consent to participate: the protocol was approved by the Institutional Review Board of Louisiana State University Health Sciences Center Shreveport (FWA 00000653, 00000178 IRB) on May 9, 2023. Our retrospective observational study protocol was designed to examine electronic medical records (IRB approved protocol number STUDY00002388) by first assigning study subject numbers to anonymize the data set. IRB waived any requirement for signed informed consent.

Availability of data and materials: all the data used for this research are available, upon reasonable request, from the Louisiana State University Health Sciences Center Shreveport, USA.

Funding: this research received no external funding.

Acknowledgments: the authors want to acknowledge Runhua Shi, MD, PhD Statistician, and Professor of Internal Medicine, Louisiana State University Health Sciences Center at Shreveport for his contributions in generating statistical methods, tables, and figures in this manuscript. Moreover, they are grateful to the Paolo Procacci Foundation for the support in the publishing process.

Received: 26 February 2024.

Accepted: 3 June 2024.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

©Copyright: the Author(s), 2024

Licensee PAGEPress, Italy

Advancements in Health Research 2024; 1:5

doi: 10.4081/ahr.2024.5

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial International License (CC BY-NC 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

<sup>1</sup>Department of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, LA, USA; <sup>2</sup>Department of Anesthesia and Perioperative Care, University of California, San Francisco, USA; <sup>3</sup>School of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, USA; <sup>4</sup>Department of Emergency Medicine, Faculty of Public Health, Medical University of Silesia, Bytom, Poland; <sup>5</sup>Paolo Procacci Foundation, Rome, Italy; <sup>6</sup>Professor, Pain Fellowship Director, Vice Chairman, Department of Anesthesiology; Professor, Department of Pharmacology, Toxicology, and Neurosciences, Louisiana State University Health Sciences Center at Shreveport, LA, USA

## ABSTRACT

After cardiopulmonary bypass (CPB) approximately 20% of patients require platelets. In our safety-net hospital, the incidence of platelet transfusion is over 40%, perhaps attributable to our prevalent risk factors of renal dysfunction, CPB duration, and absence of tranexamic acid (TXA). We designed this retrospective observational study after surgeons decided against offering CPB in the presence of these risk factors. The Institutional Review Board (IRB) approved the protocol and waived informed consent. Our hypothesis was the number of platelet transfusions in the consecutive patients during the first ninety days of 2022 would be higher than those in 2023. Confounders included platelet counts and hemoglobin immediately before platelet transfusion. Secondary outcomes were postoperative day two creatinine and other components transfused. Preoperatively creatinine trended higher in 2022 at 1.5 vs 1.1, reaching significance postoperatively at 1.9 vs 1.1 ( $p=0.02$ ). CPB decreased from 174 to 124 min ( $p=0.06$ ). TXA use increased from 18 of 28 to 26 of 29 patients. Platelets during CPB increased (142 to 173,  $p=0.06$ ). Hemoglobin nadirs rose (8 g/dL to 8.8,  $p=0.04$ ). Platelet units transfused per patient tended to rise ( $0.7\pm 1$  vs  $0.93\pm 1.5$ ); if exposed, patients tended to receive more units ( $2.1\pm 1.3$  vs  $2.5\pm 1.4$ ) sooner. These data support a need for thromboelastograms with platelet mapping immediately post-CPB.

## Introduction

Platelets in recent years have been in short supply and high demand. In our safety-net hospital, the incidence of platelet transfusion after cardiac surgery is over 40%, placing us at the high end of the normal range reported across North America. Renal dysfunction, long cardiopulmonary bypass (CPB) times, and absence of tranexamic acid (TXA) are well-described major risk factors for requiring platelet transfusions. Patient blood management protocols (PBM) should be individualized accord-

ing to each hospital's demonstrated needs. Thromboelastograms (TEG) are one method to prevent unnecessary platelet transfusions, but their efficacy in cardiac surgery is not as well studied as in other settings.<sup>1</sup>

Our institution is a safety-net hospital, constrained by finances and staffing, preventing us from purchasing a point-of-care TEG. However, we have a TEG that requires hours for results, and about \$700 vs \$50 for a platelet count. Staffing limitations prevented prolonged intensive care unit (ICU) stay, necessitating that the surgical department after summer of 2022 offered CPB only if expected duration was shorter and kidney function better, along with requiring TXA be administered uniformly. Our hypothesis was that this intervention would not only reduce length of stay but also platelet transfusions. Therefore, we retrospectively compared the incidence of transfusions of all blood components within one week of heart surgery for consecutive patients during the first three months of 2022 to those during the first three months of 2023. We selected these time periods because of a decision to reduce length of stay happened to involve similar risk factors that are known to reduce blood transfusions. Specifically, in the summer of 2022, the surgeons decided to operate only if kidney function preserved and duration of surgery short, and instituted uniform administration of TXA. We waited another few months after the decision in the summer to allow for standardized approaches and to maintain the same seasonal variations in hospitalizations.

## Materials and Methods

This study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Louisiana State University Health Sciences Center Shreveport on May 9, 2023. Our retrospective observational study protocol was designed to examine electronic medical records (IRB approved protocol number STUDY00002388) by first assigning a new study subject number into the data set, masking any personal information, thereby introducing negligible risk of loss of privacy. Furthermore, because retrospective chart review cannot be practically carried out without the waiver, as it is not practical to contact this many patients, IRB waived any requirement for each individual to sign informed consent. The authorization of research use and disclosure of protected health information by signed informed consent was also waived based upon an IRB general statement. Therefore, our study was in compliance with the terms of the Health Insurance Portability and Accountability Act of 1996 of the United States. All the data used for this research are available, upon reasonable request, from the Louisiana State University Health Sciences Center Shreveport, USA.

We compared all 32 consecutive patients undergoing CPB from January through March in 2022 to the 29 patients from January through March in 2023. Exclusion criteria included protected classes of pediatrics, pregnancy, prisoners, and anyone cognitively impaired.

Our primary outcome variable was how early was the timing of each platelet transfusion, in terms of hours after separation from CPB through 7 days postoperatively. Secondary outcome variables included: creatinine at postoperative day two, along with total number of platelet units, fresh frozen plasma (FFP), cryoprecipitate (CRYO), and packed red blood cells (PRBC) transfused within 7 days. Confounders included preoperative creatinine, duration of CPB, TXA dose, age, weight, height, an-

ticoagulants, gender, and platelet and hemoglobin values immediately preceding platelet transfusion.

### Statistical analysis

We used SAS 9.3 software to plot all results and then found they were normally distributed. So, we used two tailed unpaired *t* tests to compare the two groups (surgery in 2022 vs 2023) preoperative characteristics and outcomes. Blood salvage was not analyzed because of uniform application. For categorical variables we used Chi square (and Fisher exact). A professor with a PhD in statistics checked the statistics and found *t*-tests sufficiently appropriate for this small study. This is an initial pilot study to discover incidence of platelet transfusion after institution of as many practical improvements to reduce risk of transfusion as feasible, so the study is small and will not be expected to meet significance. Sample size calculations indicated 164 subjects at 80% power and 0.05% alpha could show a decrease from 40% to 20% of platelet transfusion exposure, which was what we need to be more at the national average of 20% exposure. We believed these 3 interventions were the only improvements we could make to patient blood management. The numbers of heart surgeries per year are only approximately 120, making this feasible.

Significant differences in means and standard deviations were compared using two tailed unpaired *t*-tests with SAS 9.3 software, after demonstrating parametric distribution. CPB did not include retrograde arterial prime (which boosts hemoglobin), return of autologous blood siphoned off prior to exposure to tubing of CPB, nor Hemobag collection-system of pump salvage. Cell saver (inferior to Hemobag in terms of preserving platelets) was used to salvage the blood after CPB in pump tubing. Dosing for TXA by protocol was 1 gram followed by 1 mg/kg/h, although we compared dose in 2022 to 2023 to check for compliance.

## Results

After excluding 4 prisoners in 2022, 57 patients were evaluated: 28 in 2022 and 29 in 2023 (Table 1). Coronary artery bypass grafting was performed during CPB at an equally prevalent rate (65%) among both groups. Table 1 shows preoperatively creatinine tended to be higher in 2022 at  $1.5\pm 1.6$  vs  $1.1\pm 0.4$ . Table 2 shows creatinine difference reaching significance postoperatively at  $1.9\pm 1.7$  vs  $1.1\pm 0.4$  ( $p=0.02$ ). Bypass times decreased from  $174\pm 97$  to  $124\pm 98$  min ( $p=0.06$ ). TXA use increased from 18 of 28 to 26 of 29 patients. Platelet counts increased on bypass from  $142\pm 49$  to  $173\pm 72$  ( $p=0.06$ ). Platelet and hemoglobin nadirs were higher (day 3:  $8\text{g/dL}$  vs  $8.8$ ,  $p=0.04$ ;  $98$  vs  $138$ ,  $p=0.005$ ). Platelet units transfused per patient tended to increase ( $0.75\pm 1$  vs  $0.9\pm 1.5$ ); if exposed, patients tended to receive more units ( $2.1\pm 1.3$  vs  $2.5\pm 1.4$ ) sooner. Platelet counts were drawn an hour earlier before termination of CPB ( $1.6$  vs  $2.6$ ,  $p=0.03$ ). Essentially the same number of platelet counts ( $5.6$  in 2022 vs  $4.9$  in 2023,  $p=0.11$ ) were drawn within 48 hours in both groups. Platelet counts rose from 105 to 138 before transfusing the first unit of platelets ( $p=0.10$ , Figure 1) and 93 to 133 before the second unit in 2023 ( $p=0.15$ ). TEG data was available in only 2 patients, only in the intensive care unit and only in 2022. Platelet and hemoglobin nadirs were higher and occurred at day 3 ( $8\text{g/dL}$  vs  $8.8\text{g/dL}$ ,  $p=0.04$ ;  $98$  vs  $138$ ,  $p=0.005$ ). Hemoglobin before the second platelet transfusion was significantly lower in 2022 ( $7.7\text{g/dL}$  vs  $9.5\text{g/dL}$ ,  $p=0.03$ ). Transfusions for red cells tended to drop from  $2.0\pm 2.9$  to  $1.4\pm 2.5$  units, within 7 days. This trend toward fewer average PRBC transfusions per



patient began within the first 48 hours, dropping from 2.0 to 1.2 (p=0.28). Cryoprecipitate tended to rise from 0.36±0.78 units per patient to 0.69±1.25 in 2023 (p=0.23). FFP tended to decline

from 0.93±2.4 to 0.83±1.4 units per patient (p=0.84). The average number of units of platelets transfused per patient non-significantly rose from 0.75±1.04 to 0.93±1.5 (p=0.59). If exposed

**Table 1.** Pre-bypass characteristics expressed as mean±SD.

	2022	2023	p-value
Number of subjects (male;female)	22;6 (=28)	21;7 (=29)	
Number was after excluding =	4	0	
Performed TEG (all in ICU)	2	0	
Age (years)	57±11	61±9	0.10
Duration of CPB (minutes)	174 ±97	124±98	0.0589*
Hgb preop (g/dL)	12.9±2.5	13.0±2.4	0.83
Hgb during CPB (g/dL)	8.9±1.4	8.9±1.7	0.99
Platelets preop (1,000's per µL)	223±66	256±117	0.19
Platelets preCPB term (hours)	74±117	86±148	0.73
Platelet drawn preCPB term (hours)	2.6±2.2	1.6±0.98	0.03*
Platelets during CPB (1,000's per µL)	142±49	173±72	0.058*
Creatinine preop (mg/dL)	1.52±1.63	1.06±0.38	0.175
Weight (kg)	84±16	89±23	0.32
Height (cm)	172±11	176±11	0.17

SD, standard deviation; TEG, thromboelastograms; ICU, intensive care unit; CPB, cardiopulmonary bypass; \*significant at p<0.05 with t-test.

**Table 2.** Outcomes after cardiopulmonary bypass.

Values	Minimum	Maximum	Significance
Lowest platelet count postCPB term	98±43	138±59	0.005*
How long postCPB term (hours)	32±24	30±35	0.86
Lowest Hgb postCPB in 7 days (g/dL)	8.0±1.6	8.8±1.32	0.037*
How long postCPB term (hours)	64±49	72±49	0.54
Average PRBC in 7 days (units)	2.04 ± 2.90	1.38±2.50	0.36
Number patients on clopidogrel preop	10	10	
Creatinine 48 hours postCPB term	1.92±1.72	1.10±0.44	0.023*
Average Platelets transfused per pt	0.75±1.04	0.93±1.5	0.59
If transfused, average number platelets	2.08±1.26	2.45±1.37	0.49
Number of patients given platelets	13	11	χ <sup>2</sup> NS
Hours postCPB received 1 <sup>st</sup> platelet	7.5±13.4	4.1±6.4	0.42
Platelet count prior to 1 <sup>st</sup> platelet	105± 41	138±52	0.10***
Platelet count drawn hours post CPB	6.2±13	2.8±4.8	0.37
Hours post CPB received 2 <sup>nd</sup> platelet	8.8±16	1.6±2.9	0.26
Platelet count value prior to 2 <sup>nd</sup> platelet	9 ±42	133±61	0.146
Hrs postCPB received 3 <sup>rd</sup> platelet	3±4	5.5±11	0.72
Platelet count prior to 3 <sup>rd</sup> platelet	46±13	101±32	0.04*
Hrs post CPB received 4 <sup>th</sup> platelet	66±94	11±17	0.55
Platelet count hours postCPB for 4 <sup>th</sup>	46±12	77±7.5	0.11
FFP average # units	0.93±2.4	0.83±1.36	0.84
Cryo average # units	0.36±0.78	0.69 ±1.25	0.23
PRBC average # units within 48 hours	1.97±2.95	1.21±2.16	0.28
Hgb before 1 <sup>st</sup> platelet	8.6 ±1.7	9.3±1.8	0.38
Hgb before 2 <sup>nd</sup> platelet	7.7±0.67	9.5±1.89	0.03*
Hgb before 3 <sup>rd</sup> platelet	7.85±0.3	8.75±1.4	0.29
Hgb before 4 <sup>th</sup> platelet	8.75±1.48	8.4±1.5	0.81
Number of platelets counts in 48 hours	5.6±2.0	4.9±1.3	0.11

CPB, cardiopulmonary bypass; PRBC, packed red blood cell; NS, not significant; \*p<0.05; \*\*\*p<0.001.


to platelets, the average number of units tended to rise from  $2.1 \pm 1.3$  to  $2.5 \pm 1.4$  ( $p=0.49$ ). Exposure differences are equivocal, with 11 of 29 patients in 2023 receiving platelets versus 13 of 28 in 2022 (Table 3,  $p=0.5$ ). In 2022, the first unit of platelets tended to be administered later ( $7.5 \pm 13$  vs  $4.1 \pm 6$  h,  $p=0.4$ , Figure 2). In 2022, 8 of the 13 patients receiving platelets received a second unit, while in 2023, 5 of the 11 had a second unit. The second unit of platelets was given after platelet counts were available from a blood draw on average 1.6 h after termination of CPB in 2023 vs 8.8 h in 2022 ( $p=0.26$ ). The timing of platelet transfusion was sooner (Figure 3). Four patients received a 3rd bag in 2023 compared to 2 patients in 2022 at a significantly higher platelet count in 2023 ( $101$  vs  $46$ ,  $p=0.04$ ). Three patients received a 4<sup>th</sup> bag in 2023 compared to 1 patient in 2022.

## Discussion

We found a trend toward fewer patients transfused with platelets immediately after bypass under these three conditions: creatinine is low, predicted surgery duration is short, and TXA is uniformly administered. These were the only modifiable risk factors feasible to improve. Unfortunately, a trend emerged toward more platelet transfusions per patient in 2023 that may indicate two future research areas. First, uniform algorithms can indicate cut-off values of post-CPB point-of-care TEG that would trigger first correcting coagulation with cryoprecipitate and FFP rather than blindly and urgently transfusing platelets. Second, platelet mapping TEG could be done preoperatively to better time delay of surgery in the presence of aspirin and clopidogrel, especially since one third of our patients had clopidogrel recently.

**Table 3.** Platelet transfusion exposure. Platelets were received in N patients within 48 h ( $p=0.5$ ; 0.042 value  $\chi^2$ ) with Fishers Exact test two-sided probability,  $p=0.596$ .


	2022	2023
Yes	13	11
No	15	18




**Figure 1.** Prior to transfusion of the first unit of platelets, the percentage of study population with each specific platelet level. Median and interquartile ranges are on bottom panel box plots.

This is the first study we are aware of that examines the *timing* of platelet transfusions after separation from bypass, relative to platelet and hemoglobin levels. Our protocol remained measurement of one platelet count during bypass, but prothrombin only hours after arrival in intensive care. Our study measured confounders of age, weight, height, anemia, anticoagulants, duration of CPB, and creatinine based upon previous research.<sup>2,3</sup> Despite a conscious shift toward preoperative selection of patients with better renal function, requiring shorter surgeries, and universal TXA, more platelets tended to be transfused earlier. Also contrary to what we expected, platelet count and hemoglobin were higher immediately prior to platelet transfusions.

Lower length of stay and components transfused are sometimes associated with the introduction of TEG. For example, in a recent study, platelet administration fell from 27% to 16%,  $p=0.001$ . These investigators obtained point-of-care (POC-TEG)



**Figure 2.** Prior to transfusion of the first unit of platelets, the percentage of study (y-axis) population waiting how many hours (x-axis) between time from termination of cardiopulmonary bypass to transfusion.



**Figure 3.** Percent of study population compared to the number of platelet units transfused within 48 hours, showing that in 2023 more pairs of platelets tended to be administered earlier.



results within a couple of min. However, average number of platelet units transfused per patient did not decline.<sup>4</sup> In their data, mortality was only 2.5% and re-exploration rate was only 2%. In a safety-net hospital such as ours, patients often have more platelet dysfunction arising from more comorbidities, and thus may be expected to require more platelet transfusions. A lower number needed to treat (NNT) would result from power analysis, making a safety-net hospital fertile ground for future research about POC-TEG.

Blood transfusion contributes to mortality. After hours of severe hemorrhage, necessitating massive blood transfusions, re-exploration for tamponade may be required. Acute kidney injury may develop after these hemodynamic stressors. Deppe et al. found TEG was not associated with decrease in duration of intensive care unit or hospital length of stay, stroke, or mortality.<sup>5</sup> However, they found that TEG was associated with a decrease in acute kidney injury, declining from 7.8% to only 6% incidence. In Deppe's data, re-exploration rates were 4.2%, regardless of being before or after adoption of TEG, emphasizing that TEG data has shown variable results. Some authors state it is useful for reducing platelet transfusions.<sup>4,5</sup> Deppe's group showed NNT with TEG is 9 to reduce one unit of transfusion of any product, and NNT is 6.6 for FFP.<sup>5</sup> In his study, platelet use was reduced by 21%. This only represented a drop in incidence from 20.5% to 19.5% after adoption of TEG,  $p=0.03$ .<sup>5</sup>

In contrast, another study found the mean number of platelets transfused remained the same at 1.28 before instituting frequent TEG compared to 1.26 after.<sup>2</sup> Their study also found that FFP transfusions dropped by about 3-fold, and packed red blood cells per patient dropped from 2.99 to 2.38, achieving a 40% decrease in mean units of any product transfused. Astonishingly, the opposite effect was noted in Canada at 12 hospitals studied in a randomized controlled trial (RCT) comprising 7402 patients. Fewer PRBC were transfused (RR 0.9, CI 0.85-0.98,  $p=0.02$ ) but platelet transfusions were reduced the most (RR 0.77, CI 0.68-0.87). Stated another way, the Canadian study showed a 24% reduction in average number of platelets transfused per person and NNT 16.7.<sup>6</sup> Those authors summarized that an integrated transfusion algorithm reduced red blood cell transfusions, platelet transfusions, and major bleeding following cardiac surgery, without reducing fresh frozen plasma transfusion. Other research describes the TEG as *not* helpful in discriminating coagulopathy in the presence of antiplatelet medications, during obstetrical, spine, aortic or cardiac surgery, and trauma. In cardiac surgery, many patients received 30mcg/kg recombinant Factor VIIa and other treatments in the same TEG arms, confounding the results.<sup>7</sup>

During very long courses of CPB, such as ECMO, rather than a TEG, a daily PT, PTT, fibrinogen, and CBC are recommended.<sup>8</sup> During shorter CPB durations, a landmark trial compared TXA at 2 mg/kg/h vs 16 mg/kg/h.<sup>9</sup> They demonstrated allogeneic red blood cell transfusion occurred in 333 of 1525 patients (21.8%) in the high-dose group and 391 of 1506 patients (26.0%) in the low-dose group (RR 0.84;  $p=0.004$ ). Outcomes of postoperative seizure, thrombotic events, kidney dysfunction, or death occurred in 17.6% of patients in the high-dose group and 16.8% of patients in the low-dose group,  $p=0.003$ . Fourteen of the 15 prespecified secondary end points were not significantly different between groups, including seizure, which occurred in 1% in the high-dose group and 0.4% in the low-dose group (95% CI, -0.0% to 1.2%;  $p=0.05$ ). No decrease in platelet transfusions was demonstrated. A limitation of our investigation is that we administered only 1 g followed by 1 mg/kg/h in both

groups, while double or triple that dose might be more effective.

The national shortage of platelets is severe.<sup>10</sup> Our patients received an abundance of platelets in 2023, perhaps indicating a need for monitoring with POC-TEG, or they began with more unfavorable unmeasured characteristics. The American College of Surgeons (ACS) published trauma practice guidelines stating that clinical judgment remains the leading method, alongside administration of 6 PRBC, and at least 3 FFP, one cryoprecipitate 10 or 20 pack, and only thereafter one platelet apheresis.<sup>11</sup> The ACS recommends repeating platelet, fibrinogen, and hemoglobin counts every hour during massive transfusion, or until stable, and adding point-of-care TEG where available.<sup>5</sup> Two weaknesses of our study are that our TEG requires two hours and delivery to the operating room of a unit of platelets varies widely depending upon severity of daily shortages. Platelets not immediately used require placement on an agitator machine (cost \$2500) maintained in an operating room. Possibly our patients received more platelets because once delivered they must be immediately used.

Other researchers examined over 12,000 cardiac surgeries and found no association between platelet transfusion and mortality (OR 1.28, 99% CI: 0.49-3.35).<sup>12,13</sup> When matching 195 patients who received cryoprecipitate at a median time of 1.7 h after arrival in the intensive care unit with 743 controls, there was no increased mortality (OR 1.1; 99% CI 0.43-2.84) or kidney injury (OR 1.03). Decreased infections appeared in those who received platelets, which may be secondary to earlier administration synergistic with other blood components.<sup>6,12</sup> European practice guidelines list TEG as Class IIa, as helpful to "consider." However, their larger hospitals are equipped with POC-TEG.<sup>14</sup> Thromboembolic events were decreased with TEG, but length of stay and intensive care unit stay did not change.<sup>5</sup>

---

## Limitations

The greatest weakness in the present investigation is a relatively small sample size, and a lack of TEG, fibrinogen or prothrombin levels. Saillant *et al.*<sup>10</sup> comments that while TEG is important, "we routinely overlook hemostatic adjuncts that may reduce blood loss, such as RiaSTAP",<sup>15</sup> a fibrinogen concentrate. They also recommend drawing more frequent platelet counts (giving platelets if bleeding and under 100), but first correcting fibrinogen levels (giving cryoprecipitate if under 200) and prothrombin times or INR (giving FFP if greater than 1.5). The greatest strength is that, to our knowledge, this is the first study that describes *timing* between separation from bypass and each platelet transfusion.

---

## Conclusions

Patient blood management (PBM) flowcharts individualized to a cardiac surgery center need to include a specific TXA dose. In one study of 27,729 patients, only medium or high dose TXA resulted in less patients exposed to platelet transfusion, although not lower average units per patient.<sup>16</sup> A meta-analysis showed a bolus technique is equally effective in reducing the average transfused red cells by one unit as is a bolus followed by a continuous infusion.<sup>17</sup> A large randomized controlled trial showed that high doses such as 80 mg/kg vs moderate doses of 50 mg/kg are associated with average transfused units dropping from 4.1 to 2.5,  $p=0.02$ .<sup>18</sup> These investigators defined low dose as 1 g bolus and

400mg/h plus 0.5g in the CPB prime and high dose as 30 mg/kg followed by 15 mg/kg/h and 2 mg/kg in the prime.<sup>19</sup>

Second, PBM flowcharts need to include trigger values of hemoglobin, fibrinogen, and prothrombin time, or TEG before transfusion of each type of component. Our population unfortunately has high incidence of malnutrition, leading to microvascular bleeding and more platelet transfusions.<sup>20,21</sup> However, if hemoglobin is too high, viscosity is a risk factor for coronary thrombosis.<sup>22</sup> Fibrinogen has been shown to be the most important component to thicken blood and slow flow.<sup>23</sup>

To further discriminate the effect of fibrinogen upon transfusion, investigators studied TEG during bypass before and after transfusion of platelet versus cryoprecipitate, containing fibrinogen.<sup>24</sup> They found platelets improved alpha and maximal amplitude (MA), markers of fibrinogen and platelet function, respectively. Cryoprecipitate after CPB also improved MA. In cyanotic congenital heart disease, TEG showed hypofibrinogenemia but only the Sonoclot unmasked dysfunctional platelets.<sup>25</sup> Interpretation of one institution's TEG should be within the context of their comprehensive PBM.<sup>26</sup>

Similar in size to our analysis, a study of 28 infants without TEG retrospectively, followed by 40 with TEG prospectively demonstrated fewer platelet transfusions ( $36 \pm 12$  vs  $49 \pm 27$  ml/kg,  $p=0.028$ ).<sup>27</sup> Reviews have recently elucidated the difference of TEG in determining if coagulopathy stems from platelet dysfunction or hypofibrinogenemia.<sup>28,29</sup> A relative risk of 0.77 for platelet transfusion was found during a systematic database review of various TEG technologies.<sup>30</sup> When massive trauma did not permit time for examination of lab values, the 12 PRBC:6 FFP:1 platelet ratio was not inferior to 6:6:1 ratio for mortality at 30 days; nevertheless, such anemia may result in more platelet transfusions.<sup>31</sup> Instead of waiting for hours for laboratory values, we suggest creating a local PBM algorithm beginning with higher TXA doses and ending CPB with stat fibrinogen and prothrombin time (or, better yet, POC-TEG) triggering transfusion of appropriate types of blood components.

## References

1. Chegini A. Evaluating the importance of patient blood management during COVID-19 pandemic. *Anesth Pain Med* 2022;11:e112910.
2. Fleming K, Redfern RE, March RL, et al. TEG-directed transfusion in complex cardiac surgery: Impact on blood product usage. *J Extra Corpor Technol* 2017;49:283-290.
3. Zaffar N, Joseph A, Mazer CD, et al. The rationale for platelet transfusion during cardiopulmonary bypass: an observational study. *Can J Anaesth* 2013;60:345-54.
4. Hasan O, Tung RC, Freeman H, et al. Thromboelastography after cardiopulmonary bypass: Does it save blood products? *Kans J Med* 2022;15:27-30.
5. Deppe AC, Weber C, Zimmermann J, et al. Point-of-care thromboelastography/thromboelastometry-based coagulation management in cardiac surgery: a meta-analysis of 8332 patients. *J Surg Res* 2016;203:424-33.
6. Karkouti K, Callum J, Wijeyesundera DN, et al. Point-of-care hemostatic testing in cardiac surgery: A stepped-wedge clustered randomized controlled trial. *Circulation* 2016;134:1152-62.
7. Erdoes G, Faraoni D, Koster A, et al. Perioperative considerations in management of the severely bleeding coagulopathic patient. *Anesthesiology* 2023;138:535-60.
8. Skidmore KL, Rajabi A, Nguyen, et al. Venovenous extracorporeal membrane oxygenation: Anesthetic considerations in clinical practice. *Anesthesiol Pain Med* 2023;13:e136524.
9. Shi J, Zhou C, Pan W, et al. Effect of high- vs low-dose tranexamic acid infusion on need for red blood cell transfusion and adverse events in patients undergoing cardiac surgery: The OPTIMAL randomized clinical trial. *JAMA* 2022;328:336-47.
10. Saillant NN, Kornblith LZ, Moore H, et al. The national blood shortage-An impetus for change. *Ann Surg* 2022;275:641-3.
11. American College of Surgeons. Massive transfusion in trauma. Accessed: September 27, 2023. Available from [https://www.facs.org/media/zcjdtrd1/transfusion\\_guidelines.pdf](https://www.facs.org/media/zcjdtrd1/transfusion_guidelines.pdf)
12. Fletcher CM, Hinton JV, Xing Z, et al. Platelet transfusion after cardiac surgery. *J Cardiothorac Vasc Anesth* 2023;37:528-38.
13. Hinton JV, Xing Z, Fletcher CM, et al. Cryoprecipitate transfusion after cardiac surgery. *Heart Lung Circ* 2023;32:414-23.
14. Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA), Boer C, Meesters MI, et al. 2017 EACTS/ EACTA Guidelines on patient blood management for adult cardiac surgery. *J Cardiothorac Vasc Anesth* 2018;32:88-120.
15. U.S. Food and Drug Administration. Riastap. Accessed: September 27, 2023. Available from: <https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/riastap>
16. Lin PS, Yao YT, Tian LJ, et al. The efficacy and safety of intravenous administration of tranexamic acid in patients undergoing cardiac surgery: Evidence from a single cardiovascular center. *Medicine (Baltimore)* 2023;19:102:e33819.
17. Guo J, Gao X, Ma Y, et al. Different dose regimens and administration methods of tranexamic acid in cardiac surgery: a meta-analysis of randomized trials. *BMC Anesthesiol* 2019;19:129.
18. Hodgson S, Larvin JT, Dearman C. What dose of tranexamic acid is most effective and safe for adult patients undergoing cardiac surgery? *Interact Cardiovasc Thorac Surg* 2015;21:384-8.
19. Couture P, Lebon JS, Laliberte E, et al. Low-dose versus high-dose tranexamic acid reduces the risk of nonischemic seizures after cardiac surgery with cardiopulmonary bypass. *J Cardiothorac Vasc Anesth* 2017;31:1611-7.
20. Kuhn V, Diederich L, Keller TCS 4th, et al. Red blood cell function and dysfunction: Redox regulation, nitric oxide metabolism, anemia. *Antioxid Redox Signal* 2017;26:718-42.
21. Jeong SK, Cho YI, Duey M, et al. Cardiovascular risks of anemia correction with erythrocyte stimulating agents: should blood viscosity be monitored for risk assessment? *Cardiovasc Drugs Ther* 2010;24:151-60.
22. Beris AN, Horner JS, Jariwala S, et al. Recent advances in blood rheology: a review. *Soft Matter* 2021;17:10591-613.
23. Varchanis S, Dimakopoulos Y, Wagner C, et al. How viscoelastic is human blood plasma? *Soft Matter* 2018;14:4238-51.
24. Tirota CF, Laguieruela RG, Salyakina D, et al. Interval changes in ROTEM values during cardiopulmonary bypass in pediatric cardiac surgery patients. *J Cardiothorac Surg* 2019;14:139.



25. Bhardwaj V, Malhotra P, Hasija S, et al. Coagulopathies in cyanotic cardiac patients: An analysis with three point of care testing devices. *Ann Card Anaesth* 2017;20:212-8.
26. Gorlinger K, Dirkmann D, Hanke AA. Potential values of transfusion protocols in cardiac surgery. *Curr Opin Anaesthesiol* 2013;26:230-43.
27. Naguib AN, Carrillo SA, Corridore M, et al. A ROTEM-guided algorithm aimed to reduce blood product utilization during neonatal and infant cardiac surgery. *J Extra Corpor Technol* 2023;55:60-9.
28. Agarwal S, Abdelmotieleb M. Viscoelastic testing in cardiac surgery. *Transfusion* 2020;60:S52-S60.
29. Demailly Z, Wurtz V, Barbay V, et al. Point-of-care viscoelastic hemostatic assays in cardiac surgery patients: Comparison of thromboelastography 6S, Thromboelastometry Sigma, and Quantra. *J Cardiothorac Vasc Anesth* 2023;37:948-55.
30. Whiting P, Al M, Westwood M, et al. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of hemostasis: a systematic review and cost-effectiveness analysis. *Health Technol Assess* 2015;19:1-228.
31. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. *JAMA* 2015;313:471-82.

Non-commercial use only